According to a study in mice, semaglutide treatment may stimulate FGF21 in mouse liver and improve FGF21 sensitivity, suggesting an important role of the GLP-1/FGF21 axis in mediating beneficial effects in obesity [90]. The gene discussed is GLP1R; the disease is obesity disorder.